TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05768269: A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

Sponsor: Century Therapeutics, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 375 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT05768269 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05768269 Rescue Dossier →